DWTX Company Profile and Key Details

Dogwood Therapeutics, Inc. has 1.91 million shares outstanding. The public float is 1.62 million shares, elevated short interest at 2.24% of float. This equals 37.86 thousand shares. The short ratio is 2.21 days. Institutional investors hold 6.81% of the float. Insiders own 13.07%.

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) closed at $1.85 USD, gaining $0.15 (8.82%) from the previous close of $1.70. The stock is currently mid-range between its 52-week high and low $1.28 and $9.50. With a market capitalization of about $3.54 million, Dogwood Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.70). Key stats such as the average daily volume over the past year has been around 97.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Alpharetta, GA, Dogwood Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gregory Duncan, the company employs approximately 12 people and listed since December 17, 2020. Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

DWTX has shown weak momentum, losing -8.97% over the past week and -52.43% over the past quarter, though year-to-date performance is down -34.13%. Short-term trend indicators are bullishly aligned (SMA20 -6.76%, SMA50 -22.48%, SMA200 -43.91%). The stock’s 14-day RSI is 37.7 (weak momentum), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.21% below its high and over 6.15% above its low. Average 10-day trading volume of 89.82 thousand shares is in line with the 3-month average of 86.00 thousand, indicating normal recent market interest.

Dogwood Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.77. This means the shares are trading above this model’s fair value.

Dogwood Therapeutics, Inc. generated EPS of -$24.93 over the past year. Five-year average earnings growth is -10.88%. Wall Street analysts project EPS growth of 33.69% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $12.00. The high target offers 548.65% upside. The low target suggests 548.65% downside. The mean target is $12.00. This offers 548.65% upside. Dogwood Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -31.82%. The prior quarter beat by -69.77%. Over the last six quarters, Apple has recorded several small beats. These include 333.6% in February 26, 2025.

Dogwood Therapeutics, Inc. trades at a P/E ratio of -2.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.76 suggesting the stock is closer to book value. The P/FCF stands at -0.22, also above market averages.

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) shares are down -34.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Dogwood Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.00, suggesting 548.65% upside. Our AI forecast model points to short-term strength (8.11% over two weeks), a medium-term fall (-35.68% over three months), and a longer-term loss (-82.16% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Dogwood Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.11%, with price expected at $2.00 by June 02, 2026, within a range of $1.85 to $2.16 3-Month Outlook: Projected fall of -35.68%, reaching $1.19 by August 17, 2026, with a range of $0.51 to $1.50. 1-Year Outlook: Projected loss of -82.16%, with price at $0.33 by May 19, 2027, within a range of $0.00 to $0.00.